Ob/Gyn Articles

Ob/Gyn

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The trial also found that changes in breast density were neutral or slightly decreased in the arzoxifene group, and there was no evidence of endometrial hyperplasia or carcinoma, based on central review of baseline and follow–up endometrial biopsies. Nor were there any significant differences between groups in endometrial thickness, as assessed by transvaginal ultrasonography, or in the incidence of uterine polyps, vaginal bleeding, and hot flushes.

Related Articles

Osteologix to Continue Development of Osteoporosis Drug
Internet Source, 10/21/09    Relevance Score: 93%

Lifestyle increases osteoporosis risk: docs
Internet Source, 10/21/09    Relevance Score: 90%

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Clinical Interventions in Aging, 11/12/09    Relevance Score: 89%

A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts
Bone, 10/27/09    Relevance Score: 89%

Evaluation of Compliance with Osteoporosis Treatment Guidelines After Initiation of a Pharmacist-Run Osteoporosis Service at a Family Medicine Clinic
Annals of Pharmacotherapy, 10/15/09    Relevance Score: 89%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address